Viewing Study NCT00591851

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 11:45 PM

Ignite Modification Date: 2026-01-10 @ 4:15 PM

Study NCT ID: NCT00591851

Status: COMPLETED

Last Update Posted: 2023-09-25

First Post: 2007-12-26

Is Gene Therapy: True

Has Adverse Events: True

Brief Title: Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

Sponsor: Memorial Sloan Kettering Cancer Center

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module Adverse Events Module Baseline Characteristics Module Participant Flow Module